Results 61 to 70 of about 2,912 (169)

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem.
Christopher M, Rubino, Sujata M, Bhavnani, Jeffery S, Loutit, Brooke, Lohse, Michael N, Dudley, David C, Griffith   +5 more
openaire   +2 more sources

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

Journal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm, Laura Czerkster Antochevis, Cibele Massotti Magagnin, Beatriz Arns, Tarsila Vieceli, Dariane Castro Pereira, Larissa Lutz, Ândrea Celestino de Souza, Jéssica Nesello dos Santos, Rafaela Ramalho Guerra, Gregory S. Medeiros, Lucas Santoro, Diego R. Falci, Maria Helena Rigatto, Afonso Luís Barth, Andreza Francisco Martins, Alexandre Prehn Zavascki   +16 more
doaj   +1 more source

Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance

Interdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.
Meropenem is a broad‐spectrum carbapenem antibiotic essential for treating serious infections including urinary tract infections, pneumonia, sepsis, and meningitis. This narrative review examines meropenem resistance trends and prescribing practices for severe infections in Pakistan highlighting how inappropriate use drives local antimicrobial ...
Nasim Akhtar, Ejaz Ahmed Khan, Summiya Nizamuddin, Sana Anwar, S. H. Waqar, Sarwat Faisal, Sarmad Iqbal, Divakar Sharma   +7 more
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide [PDF]

Open Forum Infectious Diseases, 2017
Abstract Background Meropenem-vaborbactam (MER-VAB) is a carbapenem-β-lactamase inhibitor combination with enhanced activity against KPC-producing Enterobacteriaceae recently evaluated in a phase 3 clinical trials for cUTIs and infections due to CRE.
Castanheira, Mariana, Mendes, Rodrigo E, Duncan, Leonard R, Woosley, Leah N, Flamm, Robert K   +4 more
openaire   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen, Rijing Zhou, Jie Fang, Jie Xiao   +3 more
wiley   +1 more source

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

Clinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg, Emily L. Heil, Suiyini Fiawoo, Jae Hyoung Lee, Sara E. Cosgrove, David M. Dobrzynski, Yihan Li, Ryan K. Shields, Emily S. Spivak, Erica J. Stohs, Pranita D. Tamma, Erin K. McCreary   +11 more
wiley   +1 more source